ODN 2088 Control (ODN 20959)

ODN 2088 Control (ODN 20959)

TLR7/8/9 antagonists consist of short single-stranded oligodeoxynucleotides. They can inhibit CpG ODN-mediated activation of TLR9 and/or activation of TLR7/8.
ODN 2088 Control (ODN 20959) is a TLR7/8 antagonist but also acts as a TLR9 antagonist control. The sequence can form G-Tetrad structures.

Background information

TLR7, TLR8 and TLR9 are prominent members of the Toll-like-receptor (TLR) family recognizing pathogen-associated molecular patterns recognizing nucleic acids
3
. Activation of these TLRs can be inhibited by short single-stranded synthetical oligodeoxyribonucleotides (ODNs)
4,6
. Several classes of and motifs for inhibitory ODN have been identified
1,6,7
.

Applications

TLR7/8/9 Antagonists can be used to inhibit TLR7/8/9 mediated cellular responses, such as activation of immune cells, human PBMCs, murine splenocytes or isolated immune cells (e.g., B cells and pDCs).
TLR7/8/9 Antagonists can be used to inhibit signaling in TLR7/8/9-
expressing recombinant cell lines.
ODN 2088 Control (ODN 20959) is can be used as a sequence control for ODN 2088
1,2,4-7
. ODN 2088 Control (ODN 20959) inhibits TLR7 and TLR8 mediated signalling but not TLR9 mediated signalling
1
.
Product options: 2

Product information

Size
Order no.
Price

ODN 2088 Control (ODN 20959)

  • For research use only
200 µg
130-105-818
-

ODN 2088 Control (ODN 20959)

  • For research use only
1 mg
130-105-814
-